Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced that it has secured the rights to use over 200 human and viral microRNA sequences in diagnostic applications, through two separate co-exclusive license agreements with Garching Innovation, the technology transfer agency of the Max Planck Society, and The Rockefeller University. The new licenses enable Exiqon, which already has a leading position in microRNA research tools, to expand into the development of diagnostic products. The terms of the agreement were not disclosed.
